

Table 3

Drugs with a statistically significant ROR and that were mentioned in at least five AKI events in the FPVD

ATC classification	Active substance (INN)	Total number of ADRs with AKI <i>n</i>	Number of ADRs with AKI when the drug is suspected alone <i>n</i> (%)	Patients requiring RRT <i>n</i> (%)	Total number of ADRs without AKI <i>n</i>	ROR	[95%CI]
Antibacterial agents for systemic use and antimycobacterial agents		523					
	Amikacin	24	8 (33.33)	7 (29.17)	78	9.37	[5.91–14.86]
	Amoxicillin	98	21 (21.43)	15 (15.31)	1617	1.88	[1.52–2.33]
	Ceftriaxone	26	1 (3.85)	6 (23.08)	481	1.63	[1.09–2.43]
	Cilastatin	8	0 (0.00)	1 (12.5)	108	2.22	[1.08–4.57]
	Ciprofloxacin	18	7 (38.89)	4 (22.22)	279	1.94	[1.2–3.14]
	Cloxacillin	24	9 (37.50)	1 (4.17)	120	6.08	[3.91–9.46]
	Daptomycin	7	2 (28.57)	0 (0.00)	57	3.69	[1.68–8.11]
	Gentamicin	53	6 (11.32)	15 (28.3)	89	18.56	[13.15–26.21]
	Imipenem	8	0 (0.00)	1 (12.5)	115	2.09	[1.02–4.29]
	Ofloxacin	16	3 (18.75)	1 (6.25)	286	1.68	[1.01–2.79]
	Piperacillin	32	0 (0.00)	3 (9.38)	429	2.26	[1.57–3.26]
	Sulfadiazine	5	4 (80)	0 (0.00)	42	3.57	[1.41–9.05]
	Sulfamethoxazole and trimethoprim	73	29 (39.73)	3 (4.11)	548	4.17	[3.25–5.36]
	Tazobactam	32	0 (0.00)	3 (9.38)	412	2.36	[1.64–3.4]
	Teicoplanin	6	2 (33.33)	0 (0.00)	55	3.28	[1.41–7.62]
	Vancomycin	67	19 (28.36)	11 (16.42)	304	6.91	[5.27–9.06]
	Rifampicin	26	4 (15.38)	1 (3.85)	325	2.42	[1.62–3.63]
Diuretics		328					
	Altizide	5	0 (0.00)	0 (0.00)	29	5.18	[2–13.4]
	Eplerenone	10	1 (10)	0 (0.00)	11	27.42	[11.62–64.68]
	Furosemide	172	20 (11.63)	21 (12.21)	358	16.5	[13.63–19.99]
	Hydrochlorothiazide	88	3 (3.41)	9 (10.23)	438	6.39	[5.05–8.09]
	Indapamide	11	0 (0.00)	2 (18.18)	140	2.36	[1.28–4.38]
	Spironolactone	42	2 (4.76)	4 (9.52)	123	10.54	[7.39–15.03]
Agents acting on the renin-angiotensin system		289					
	Candesartan	33	2 (6.06)	10 (30.3)	93	10.88	[7.28–16.25]
	Enalapril	12	1 (8.33)	1 (8.33)	86	4.21	[2.29–7.72]
	Irbesartan	22	3 (13.64)	3 (13.64)	167	3.99	[2.55–6.25]
	Lisinopril	7	1 (14.29)	0 (0.00)	30	7.02	[3.08–16.01]
	Losartan	10	1 (10.00)	2 (20.00)	41	7.35	[3.67–14.71]
	OlmесartanMedoxomil	49	6 (12.24)	8 (16.33)	201	7.55	[5.5–10.37]
	Perindopril	72	10 (13.89)	8 (11.11)	326	6.95	[5.35–9.03]
	Ramipril	49	11 (22.45)	8 (16.33)	261	5.81	[4.26–7.92]
	Telmisartan	5	0 (0.00)	0 (0.00)	39	3.85	[1.51–9.78]
	Valsartan	30	0 (0.00)	3 (10.00)	144	6.36	[4.28–9.47]

(continues)

Table 3

(Continued)

ATC classification	Active substance (INN)	Total number of ADRs with AKI <i>n</i>	Number of ADRs with AKI when the drug is suspected alone <i>n</i> (%)	Patients requiring RRT <i>n</i> (%)	Total number of ADRs without AKI <i>n</i>	ROR	[95%CI]
Antineoplastic agents		180					
	Bendamustine	20	7 (35.00)	2 (10.00)	66	9.2	[5.56–15.22]
	Cisplatin	44	20 (45.45)	8 (18.18)	130	10.46	[7.4–14.79]
	Cytarabine	17	1 (5.88)	5 (29.41)	157	3.27	[1.98–5.41]
	Etoposide	12	0 (0.00)	2 (16.67)	175	2.06	[1.15–3.71]
	Gemcitabine	13	4 (30.77)	4 (30.77)	131	2.99	[1.69–5.3]
	Melphalan	8	1 (12.50)	2 (25.00)	59	4.08	[1.94–8.55]
	Methotrexate	39	20 (51.28)	8 (20.51)	553	2.15	[1.54–2.98]
	Nivolumab	7	6 (85.71)	2 (28.57)	90	2.34	[1.08–5.05]
	Pemetrexed	13	2 (15.38)	2 (15.38)	91	4.31	[2.4–7.73]
	Vemurafenib	7	3 (42.86)	1 (14.29)	64	3.29	[1.5–7.18]
Anti-inflammatory and antirheumatic products		95					
	Diclofenac	33	12 (36.36)	4 (12.12)	161	6.27	[4.29–9.16]
	Ibuprofen	25	8 (32.00)	2 (8.00)	373	2.03	[1.35–3.05]
	Ketoprofen	26	6 (23.08)	5 (19.23)	302	2.61	[1.74–3.91]
	Naproxen	11	4 (36.36)	3 (27.27)	90	3.68	[1.96–6.9]
Drugs used in diabetes		75					
	Gliclazide	8	0 (0.00)	1 (12.50)	76	3.16	[1.52–6.57]
	Metformin	58	17 (29.31)	19 (32.76)	349	5.17	[3.89–6.86]
	Sitagliptin	9	1 (11.11)	1 (11.11)	121	2.23	[1.13–4.41]
Antivirals for systemic use		51					
	Aciclovir	37	21 (56.76)	3 (8.11)	49	23.25	[15.12–35.77]
	Valaciclovir	14	5 (35.71)	2 (14.29)	97	4.36	[2.48–7.65]
Calcium channel blockers		41					
	Amlodipine	35	0 (0.00)	7 (20.00)	328	3.26	[2.29–4.64]
	Nicardipine	6	0 (0.00)	3 (50.00)	71	2.54	[1.1–5.85]
Immunosuppressants		38					
	Ciclosporin	20	6 (30.00)	5 (25.00)	105	5.78	[3.57–9.35]
	Everolimus	7	0 (0.00)	2 (28.57)	93	2.26	[1.05–4.88]
	Tacrolimus	11	3 (27.27)	1 (9.09)	128	2.59	[1.39–4.8]
Contrast media		32					
	Iobitridol	10	4 (40.00)	2 (20.00)	79	3.81	[1.97–7.37]
	Iohexol	16	5 (31.25)	2 (12.5)	74	6.54	[3.8–11.26]
	Iopromide	6	2 (33.33)	3 (50.00)	61	2.95	[1.27–6.84]
Miscellaneous drugs		120					
	Fenofibrate	6	0 (0.00)	3 (50.00)	72	2.5	[1.09–5.76]
	Atropine	5	0 (0.00)	1 (20.00)	20	7.51	[2.81–20.04]
	Bisoprolol	17	0 (0.00)	4 (23.53)	265	1.93	[1.18–3.17]

(continues)

Table 3

(Continued)

ATC classification	Active substance (INN)	Total number of ADRs with AKI <i>n</i>	Number of ADRs with AKI when the drug is suspected alone <i>n</i> (%)	Patients requiring RRT <i>n</i> (%)	Total number of ADRs without AKI <i>n</i>	ROR	[95%CI]
	Immunoglobulins	23	7 (30.43)	15 (65.22)	361	1.92	[1.26–2.94]
	Colchicine	37	12 (32.43)	5 (13.51)	155	7.33	[5.1–10.54]
	Zoledronic acid	10	9 (90.00)	2 (20.00)	103	2.92	[1.52–5.6]
	Sevoflurane	5	1 (20.00)	0 (0.00)	9	16.69	[5.58–49.87]
	Lithium	17	11 (64.71)	3 (17.65)	240	2.14	[1.3–3.5]

ADR, adverse drug reaction; ATC, Anatomical, Therapeutic and Chemical; AKI, acute kidney injury; CI, confidence interval; FPVD, French national pharmacovigilance database; INN, international nonproprietary name; ROR, reporting odds ratio; RRT, renal replacement therapy